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Background
Strategies that enhance the function of T cells are criti-
cal for immunotherapy.
Methods
Here we described for the first time a non-viral
mediated approach to reprogram primary human T cells
by disruption of PD-1.
Results
We showed that the gene knockout of PD-1 by electro-
poration of plasmids encoding sgRNA and Cas9 was tech-
nically feasible. The disruption of PD-1 resulted in
significant reduction of PD-1 expression but didn’t affect
the viability of primary human T cells. Cellular immune
response of the gene modified T cells was characterized by
up-regulated IFN-g production and enhanced cytotoxicity.
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Conclusions
These results suggest that we have established an
approach for efficient checkpoint inhibitor disruption,
providing a new strategy for targeting checkpoint inhibi-
tors to improve the efficacy of T cell based adoptive
therapies.
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